2型糖尿病患者血清补体因子H与胰岛素抵抗相关性研究

The correlation between insulin resistance and serum complement factor H in patients with type 2 diabetes

目的探讨2型糖尿病(T2DM)患者糖脂代谢和胰岛素抵抗的变化情况,分析其与患者血清补体因子H表达之间的相关性。方法选择2015年1月至2016年2月期间T2DM的患者120例为研究对象,根据亚太地区2000年的肥胖标准分为肥胖组(64例)和非肥胖组(56例),另选择同期体检的健康人群60例为对照组。比较各组患者的血清补体因子H表达情况及空腹胰岛素、空腹血糖、血脂水平,计算胰岛素抵抗指数(HOMA-IR),分析各指标与补体因子H表达的相关性。结果肥胖组、非肥胖组、对照组血清补体因子水平分别为(196.38±23.49)mg/L、(184.34±21.48)mg/L和(173.26±18.37)mg/L,肥胖组>非肥胖组>对照组,组间比较差异有显著的统计学意义(P<0.01);T2DM患者血清补体因子H与体质指数(BMI)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、甘油三酯(TG)、空腹血糖(FBG)水平均呈正相关(r=0.397、0.601、0.333、0.312、0.524,P均<0.01),与高密度脂蛋白胆固醇(HDL-C)呈负相关(r=-0.588,P<0.01)。结论补体因子H可能参与了肥胖及T2DM的发病过程,临床上有望将补体系统作为T2DM的治疗靶点。

Objective To discuss the correlation between insulin resistance and serum complement factor H in patients with type 2 diabetes. Methods From January 2015 to February 2016,120 cases of T2 DM patients were enrolled in this study. according to 2000 standard of obesity in the asia-pacific region,they were divided into obesity group（ 64 cases） and non obesity group（ 56 cases）. And 60 healthy cases in the same period were selected as the control group. Serum complement factor H expression and fasting insulin,fasting blood glucose,blood lipid levels,insulin resistance index（ HOMA IR） were compared,and the of correlation of the indexes and complement factor H expression were analyzed.Results Serum complement factor levels of obese group,non-obese group and control group were（ 196. 38 ± 23. 49） mg / L,（ 184. 34 ± 21. 48）mg / L and（ 173. 26 ± 18. 37） mg / L,respectively,and there were significant difference（ P〈0.01）. There were positive correlation between serum complement factor H and body mass index（ BMI）,fasting insulin（ FINS）,insulin resistance index（ HOMA-IR）,triglyceride（ TG）,the level of fasting blood glucose（ FBG）（ r=0. 397,0. 601,0. 333,0. 601,0. 333,P〈0.01）,and negative relation with high-density lipoprotein cholesterol（ HDL-C）（ r=0. 588,P〈0.01）. Conclusion Complement factor H may be involved in the pathogenesis of obesity and T2 DM process,the complement system is expected to considered as clinically therapeutic targets in T2 DM patients.